MG
EWTX icon

Michael Gelband’s Edgewise Therapeutics EWTX Stock Holding History

Michael Gelband’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,672
Closed -$238K – 1677
2025
Q3 		$238K Sell
14,672
-30,583
-68% -$434K ﹤0.01% 1348
2025
Q2 		$593K Buy
+45,255
New +$653K 0.01% 1105
2024
Q3 		– Sell
-268,143
Closed -$4.83M – 1751
2024
Q2 		$4.83M Buy
+268,143
New +$4.68M 0.03% 417
2023
Q3 		– Sell
-138,227
Closed -$1.07M – 1811
2023
Q2 		$1.07M Sell
138,227
-3,624
-3% -$30.6K 0.01% 1076
2023
Q1 		$946K Buy
141,851
+23,901
+20% +$222K 0.01% 1155
2022
Q4 		$1.05M Buy
117,950
+432
+0.4% +$4.05K 0.02% 917
2022
Q3 		$1.16M Buy
117,518
+57,490
+96% +$581K 0.02% 1051
2022
Q2 		$478K Buy
+60,028
New +$454K 0.01% 1380

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Michael Gelband's EWTX Position: Q4 2025 in Review

Michael Gelband sold out of Edgewise Therapeutics (EWTX) in Q4 2025, closing a stake of 14,672 shares — an estimated $238K sold.

Michael Gelband first reported a position in EWTX in Q2 2022 and held it in 8 quarters. The position peaked at $4.83M in Q2 2024. 199 funds tracked by Wall St. Rank hold EWTX as of Q4 2025.

  • Michael Gelband reported no remaining Edgewise Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Michael Gelband sold 14,672 Edgewise Therapeutics shares in Q4 2025, an estimated $238K.
  • Michael Gelband first reported a position in Edgewise Therapeutics in Q2 2022 and held it in 8 quarters.
  • Michael Gelband's Edgewise Therapeutics position peaked at $4.83M in Q2 2024.
  • 199 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q4 2025.

Based on ExodusPoint Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.